Mesa Labs reported solid third-quarter performance with organic revenue growth and a sharp increase in operating income, driven by strength in Biopharmaceutical Development and improved profitability despite continued headwinds in Clinical Genomics China.

Mesa Laboratories, Inc. announced strong second fiscal quarter results, with total revenues increasing by 5.0% to $60.7 million and operating income surging by 34.7% to $4.7 million. Non-GAAP adjusted operating income excluding unusual items also saw a healthy increase of 6.1% and represented 25.1% of revenues, indicating robust profitability despite macroeconomic uncertainties and specific segment challenges.

Mesa Laboratories, Inc. announced its first fiscal quarter results for 2026, with total revenues reaching $59.543 million, a 2.4% increase year-over-year. Net income saw a significant 40.0% increase to $4.742 million, or $0.85 per diluted share. Despite a challenging macroeconomic environment, the company achieved 0.4% core organic revenue growth, driven by strong performance in Sterilization and Disinfection Control and Clinical Genomics (excluding China). Operating income decreased by 45.1% due to FX impacts and non-cash stock-based compensation, but non-GAAP adjusted operating income excluding unusual items was 21.7% of revenues.

Mesa Laboratories reported solid results for the fourth quarter of fiscal year 2025, with a 5.5% increase in total revenues and a significant increase in operating income. Core organic revenue growth was strong across all four divisions, and the company improved its balance sheet by reducing inventory and paying down debt.

Mesa Labs reported a 17.5% increase in revenues, driven by 12.6% organic growth and a 4.9% inorganic contribution from GKE. Operating income saw a substantial increase of 8,725%. However, the company experienced a net loss due to unrealized foreign currency losses and interest expense. Non-GAAP core organic revenues grew by 13.2%, and AOI increased by 21.2%.

Mesa Labs reported an 8.8% increase in revenues compared to the second quarter of the previous year, driven by the acquisition of GKE. Operating income significantly increased, and the company saw sequential growth in orders. However, core organic revenues declined slightly due to shipment timing in SDC and headwinds in China.

Mesa Labs reported a successful start to its first quarter of fiscal year 2025, with revenues increasing by 14.9% and operating income increasing by 940%. The company saw positive momentum in revenues, orders, profitability, and debt levels.

Mesa Labs' Q4 2024 results showed a net loss primarily due to a significant non-cash impairment charge. However, revenues increased by 6% compared to Q4 2023, driven by the GKE acquisition. Non-GAAP adjusted operating income excluding unusual items increased by 26.3%.

Mesa Labs reported a 1.5% decrease in revenue compared to the third quarter of fiscal year 2023, primarily due to a 9.0% core organic revenue decline, which was partially offset by revenue from the GKE acquisition. Non-GAAP adjusted operating income decreased by 6.8% year-over-year but increased sequentially, driven by the GKE acquisition. Gross profit percentage increased due to the GKE acquisition and improvements in the Calibration Solutions division.

Mesa Labs reported a decrease in revenues and operating income compared to the same quarter last year. Total revenues were $53.165 million, a decrease of 9.5%. Operating loss was $(60) thousand, a decrease of 101.5%. The company is implementing cost control actions expected to generate annual savings of approximately $2 million starting in 3Q24.

Mesa Labs reported a slight revenue increase of 0.4% in Q1 2024. The operating loss decreased significantly by 85.5%, and non-GAAP adjusted operating income excluding unusual items increased by 46.2%.

Mesa Labs reported a decrease in fourth quarter revenues by 5.6% and an increase in operating income by 570%. The company's performance was influenced by currency headwinds, slower biopharmaceutical spending, and a decrease in COVID-related revenues.

Mesa Labs reported a slight decrease in revenues for Q3 2023, but experienced growth in operating income and non-GAAP adjusted operating income. The company faced headwinds from currency exchange rates and COVID-19 impacts, but saw core organic revenue growth of 4.6%.

Mesa Laboratories reported a strong rebound in revenue growth for Q2 2023, reaching 12% organically and 18% on a constant currency basis. Profitability also recovered, with adjusted operating income excluding unusual items reaching 27% of revenues.

Mesa Labs announced its Q1 2023 results, revealing a 44% increase in revenues compared to the same quarter in the prior year. However, the company's operating income decreased by 247%, and net loss was $(1,438,000), a decrease of 172%. The results were impacted by headwinds from China lockdowns, FX, and continued operational constraints caused by both materials and labor shortages.

Mesa Labs reported a 55% increase in revenues for Q4 2022, reaching $58.879 million, but experienced a 103% decrease in operating income, resulting in a loss of $(110) thousand. Net loss was $(1,784) thousand, or $(0.34) per diluted share. Adjusted operating income increased by 11% to $11.653 million, or $2.22 per diluted share. Organic revenue growth was 12% for the quarter.

Mesa Labs reported a 60% increase in revenue for Q3 2022, driven by organic growth and acquisitions. However, the company experienced a decrease in operating income and reported a net loss, impacted by unusual items related to acquisitions and other adjustments.

Mesa Laboratories reported a 12% increase in revenues to $35.84 million for the second quarter of fiscal year 2022. Operating income decreased by 6% to $4.201 million, while net income increased by 39% to $3.720 million, or $0.70 per diluted share.

Mesa Labs reported a 17% increase in revenues, a 13% decrease in operating income, and a 64% increase in net income for the first quarter of fiscal year 2022. Adjusted operating income also increased by 12%. The company is focused on long-term growth and navigating economic conditions.

Mesa Labs reported an 11% increase in revenue for Q4 2021, reaching $37.96 million. Operating income increased by 318% to $4.30 million, and net income increased by 353% to $3.92 million, or $0.74 per diluted share.

Mesa Labs reported an 8% increase in revenues and a significant increase in operating income for the third quarter of FY21. However, net income decreased slightly compared to the same quarter in the prior year. The company highlighted strong performance in its Sterilization and Disinfection Control division and the impact of currency exchange rates on the Biopharmaceutical Development division.

Mesa Labs reported a 25% increase in revenue to $31.86 million for the second quarter of fiscal year 2021. However, operating income decreased by 5% to $4.47 million, and net income decreased by 16% to $2.679 million. The company's performance was impacted by unusual items, but adjusted operating income, excluding these items, increased by 41%.

Mesa Labs' first quarter results showed a 14% increase in revenues, but a 41% decrease in operating income and a 78% decrease in net income. Organic revenues declined by 4%. Adjusted operating income decreased 1%.

Mesa Labs reported a 29% increase in revenues for Q4 2020, reaching $34.208 million. However, operating income decreased by 65% to $899,000, and the company experienced a net loss of $1.680 million, or $(0.37) per diluted share. Excluding unusual items, adjusted operating income increased by 32%.

Mesa Labs reported a 19% increase in third quarter revenues to $31.655 million. However, operating income decreased by 356% to $(3.381) million, and net income decreased by 640% to $(4.630) million, or $(1.06) per diluted share. Excluding unusual items, operating income would have increased 5% to $5.255 million.